Compare AbCellera Biologics Inc (ABCL) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Energy Select Sector SPDR Fund — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Energy Select Sector SPDR Fund trades at $55.68. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Energy Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ABCL | XLE | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $62.57 |
52-Week Low | $2.78 | $42.12 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
XLE trades at $53.13, down 0.17% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF has gained 21% year-to-date, ranking among top-performing sector SPDRs according to ETF Trends on July 2, 2026. Recent news highlights oil price volatility and geopolitical developments affecting energy sector performance, while a dividend of $0.38 is scheduled for June 2026.
Outlook remains mixed with technical weakness offset by strong YTD performance. Investment opportunity exists for investors seeking energy sector exposure amid ongoing oil market volatility, though risks include geopolitical tensions and potential Federal Reserve rate hikes that could pressure the sector. The neutral oscillator reading suggests potential for near-term stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
